Afatinib: A Review in Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Afatinib: A Review in Advanced Non-Small Cell Lung Cancer

Published:2016-11-22 Issue:6 Volume:11 Page:825-835
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Keating Gillian M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-016-0465-2.pdf

Reference37 articles.

1. Hall PE, Spicer J, Popat S. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncol. 2015;11(15):2175–91.

2. National Comprehensive Cancer Network. Non-small cell lung cancer: NCCN clinical practice guidelines in oncology (version 1.2017). 2016. http://www.nccn.org/. Accessed 24 Oct 2016.

3. Modjtahedi H, Cho BC, Michel MC, et al. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(6):505–21.

4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–25.

5. Boehringer Ingelheim International GmbH. Gilotrif® (afatinib) tablets, for oral use: US prescribing information. 2016. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf . Accessed 24 Oct 2016.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AFATINIB-A COMPREHENSIVE REVIEW OF ANALYTICAL METHODS DEVELOPED IN PHARMACEUTICALS AND BIOLOGICAL MATRICES;International Journal of Applied Pharmaceutics;2024-07-07

2. Nephrotoxicity of targeted therapy used to treat lung cancer;Frontiers in Immunology;2024-07-04

3. Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment;Clinical and Translational Oncology;2024-05-25

4. Recent Advances in FDA-Approved Kinase Inhibitors Targeting Lung Cancer;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

5. Intrinsic disorder and flexibility in proteins: a challenge for structural biology and drug design;Crystallography Reviews;2023-04-03